Navigation path

Community Register of medicinal products

Community register of orphan medicinal products


GRANTED  

Product information

Iduronate-2-sulfatase

EU orphan designation number: EU/3/01/078   
Active ingredient: Iduronate-2-sulfatase
Indication: Treatment of Mucopolysaccharidosis, type II (Hunter Syndrome)
Sponsor: Shire Human Genetic Therapies AB
Rinkebyvägen 11B, SE-182 36 Danderyd, Sverige
EU Centralised marketing authorisation: A centralised EU marketing authorisation has been obtained under the name Elaprase on 08/01/2007 with the number EU/1/06/365

   Public summary of scientific opinion     EPAR

 

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
11/12/2001 Centralised Orphan - Designation EMEA/OD/045/01 (2001)4111 of 11/12/2001
27/05/2005 Other procedure -
03/01/2006 Centralised Orphan - Transfer of orphan designation EMEA/OD/056/01/T/01 (2005)5977 of 23/12/2005
25/02/2010 Other procedure -